Skip to main content

RiVive FDA Approval History

Last updated by Judith Stewart, BPharm on Aug 1, 2023.

FDA Approved: Yes (First approved July 28, 2023)
Brand name: RiVive
Generic name: naloxone hydrochloride
Dosage form: Nasal Spray
Company: Harm Reduction Therapeutics, Inc.
Treatment for: Opioid Overdose

RiVive (naloxone hydrochloride) is an over-the-counter (OTC) opioid antagonist nasal spray indicated for the emergency treatment of opioid overdose.

Development timeline for RiVive

Jul 28, 2023Approval FDA Approves RiVive (naloxone hydrochloride) Over-the-Counter Nasal Spray for the Emergency Treatment of Opioid Overdose
Dec 26, 2022Harm Reduction Therapeutics' New Drug Application for RiViveā„¢ Over-the-Counter Naloxone Nasal Spray Accepted and Granted Priority Review by FDA

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.